{"filing":{"accession_number":"0001628280-26-040051","cik":"0001253689","ticker":"CBIO","company_name":"CRESCENT BIOPHARMA, INC.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"cbio-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040051/cbio-20260602.htm"},"events":[{"id":7290,"run_id":6400,"accession_number":"0001628280-26-040051","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from Crescent Biopharma's June 2, 2026 annual general meeting, filed under Item 5.07. The filing reports detailed vote tallies for four proposals: election of two Class II directors (Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed. This is material as director elections and auditor ratification directly affect corporate governance and investor confidence.","company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4124,"accession_number":"0001628280-26-040051","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Crescent Biopharma's June 2, 2026 annual general meeting, filed under Item 5.07. The filing reports detailed vote tallies for four proposals: election of two Class II directors (Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed. This is material as director elections and auditor ratification directly affect corporate governance and investor confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:49:18.110022+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4124,"accession_number":"0001628280-26-040051","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Crescent Biopharma's June 2, 2026 annual general meeting, filed under Item 5.07. The filing reports detailed vote tallies for four proposals: election of two Class II directors (Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed. This is material as director elections and auditor ratification directly affect corporate governance and investor confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:49:18.110022+00:00","company_name":"CRESCENT BIOPHARMA, INC.","ticker":"CBIO","filing_date":"2026-06-03"}]}